Search
NRP369
go.drugbank.com/drugs/DB06384ExperimentalNRP369 is an oxycodone derivative under investigation for the treatment of pain (moderate to moderately severe). NRP369 was developed by New River Pharmaceuticals as a backup therapeutic to [NRP290].
Prostaglandin G2
go.drugbank.com/drugs/DB03866ExperimentalA cyclic endoperoxide intermediate produced by the action of CYCLOOXYGENASE on ARACHIDONIC ACID. It is further converted by a series of specific enzymes to the series 2 prostaglandins. [PubChem]
Galidesivir
go.drugbank.com/drugs/DB11676Investigational[L12039,L12084] Phase 1 clinical trials have begun to determine the safety of this drug in humans. … [L12042] Because of its activity against other coronaviruses, it may be studied as a potential therapy for COVID-19.
Norgestrienone
go.drugbank.com/drugs/DB13563ExperimentalCategories: Sex Hormones and Modulators of the Genital SystemAICA ribonucleotide
go.drugbank.com/drugs/DB01700InvestigationalThe drug was first used in the 1980s as a method to preserve blood flow to the heart during surgery and is currently of interest as a potential treatment for diabetes by increasing the metabolic activity … of tissues by changing the physical composition of muscle.
Nordazepam
go.drugbank.com/drugs/DB14028InvestigationalAn intermediate in the metabolism of DIAZEPAM to OXAZEPAM. It may have actions similar to those of diazepam.
CRx-139
go.drugbank.com/drugs/DB05744ExperimentalThe synergistic combination containing low doses of the glucocorticoid steroid prednisolone and the antidepressant paroxetine. … It is a dissociated steroid designed to enhance the immuno-modulatory activity of a low-dose glucocorticoid steroid without a comparable increase in steroid-related side effects.
TG-1042
go.drugbank.com/drugs/DB18435InvestigationalTG-1042 (formerly known as ASN-002) is a recombinant adenovirus carrying the cDNA coding sequence for the human interferon gamma gene.
Sirna-027
go.drugbank.com/drugs/DB05896InvestigationalIt is used to treat Macular degeneration. … VEGFR-1 is a key component of the clinically validated vascular endothelial growth factor (VEGF) pathway. Sirna-027 is developed by Sirna Therapeutics and is under the phase I of clinical trails.
KC706
go.drugbank.com/drugs/DB05157InvestigationalKC706 is a novel anti-inflammatory drug that works by inhibiting the activity of p38 MAP kinase. … KC706 holds potential to treat inflammatory conditions such as rheumatoid arthritis, psoriasis, inflammatory bowel disease and cardiovascular disease.